

Appendix 2 (as submitted by the authors)

**Appendix Table 2A: Crude and adjusted risk estimates for hepatic events requiring hospitalization and followed by premature cessation of LTBI therapy - by regimen**

Adverse Event	INH n / cohort (rate per 100 persons)	RIF n / cohort (rate per 100 persons)	Crude OR INH:RIF (95% CI)	Adjusted OR <sup>1</sup> INH:RIF (95% CI)	Adjusted OR <sup>2</sup> INH:RIF (95% CI)
Hepatic	24 / 8686 (0.3)	1 / 459 (0.2)	1.3 (0.2-9.4)	2.2 (0.3-16.3)	2.1 (0.3-15.5)

1. OR adjusted for sex, age cohort and previous liver disease.

2. OR adjusted for sex, age cohort and Charlson score.

See methods for details.

Abbreviations: INH = isoniazid; RIF, rifampin; OR = odds ratio; CI = confidence interval.

**Appendix Table 2B: Adjusted odds ratios of covariates associated with hepatic events requiring hospitalization and followed by premature cessation of LTBI therapy**

Factor	Comparison	Outcome
		Hepatic AE OR (95% CI)
Regimen <sup>1</sup>	INH vs RIF	2.1 (0.3-15.5)
Sex <sup>1</sup>	Female vs Male	1.6 (0.7-3.8)
Age <sup>1</sup>	36-50 vs ≤35	1.2 (0.2-7.1)
	51-65 vs ≤35	3.3 (0.6-17.6)
	>65 vs ≤35	10.2 (2.0-50.5)
Prior liver disease <sup>2</sup>	Prior vs None	15.4 (4.8-49.5)
Charlson score <sup>1</sup>	1 vs 0	3.7 (1.2-10.3)
	2 vs 0	1.9 (0.5-8.1)
	3 vs 0	3.2 (0.6-16.6)
	≥4 vs 0	2.9 (0.6-14.9)

1. OR with sex, age cohort, regimen and Charlson score variables included in logistic model.

2. OR with sex, age cohort, regimen and prior liver disease variables included in logistic model.

See methods for details.

Abbreviations: INH = isoniazid; RIF = rifampin; AE = adverse event; OR = odds ratio; CI = confidence interval.